Methotrexate for generalized granuloma annulare: A 60% response rate in a retrospective case series of 15 patients

Ixekizumab rapidly improves inflammatory markers in patients with generalized pustular psoriasis

“…5 Moreover, two recent case reports have shown improvement in PTM after teprotumumab infusions. 6,7 We retrospectively assessed response to treatment in a cohort of patients with PTM who received teprotumumab for TED. This study was reviewed and approved by the University of Miami institutional review board, #20210492 and #20210489.…”

Granulomatous slack skin: clinical characteristics, prognosis and response to therapy. A study from the Cutaneous Lymphoma French Study Group

“…Methotrexate is known to be an effective drug in MF (overall response rate of 70% among all subtypes taken together), 6 as well as in granulomatous inflammatory skin diseases, such as granuloma annulare. 7 It could thus be effective on both tumoral and granulomatous components.…”

“…Gilles Battesti iD , 1 Caroline Ram-Wolff, 1 Gabor Dobos, 1 Franc ßois Aubin, 2 Marie-Paule Algros, 3 Emmanuella Guenova iD , 4,5,6 Pascal Joly, 7 Philippe Courville, 8 Samia Mourah, 9,10 Jean-Michel Cayuela, 11 Jean-David Bouaziz, 1,10 H el ene Moins-Teisserenc iD , 11 Maxime Battistella, 10,12 Marie-Dominique Vignon-Pennamen, 12 Jacqueline Rivet, 12 Martine Bagot iD , 1,10 Ad ele de Masson iD 1,10 and the Cutaneous Lymphoma French Study Group…”

“…7 Screening for psychiatric comorbidities and traits, such as the tendency towards having social anxiety, may help implement effective nonpharmacological and pharmacological interventions. 7 Thus, a multipronged approach to HS treatment, involving both pharmacological and psychosocial interventions, may help decrease HS burden and improve QoL. The use of online support groups may also provide an accessible and effective intervention for patients with HS.…”

Acute onset painful acral granuloma annulare: Work-up and therapeutic strategies

“…Indeed, methotrexate, a therapeutic option proposed by the authors, represents one such management strategy, with a recent case-series of 15 generalized GA patients demonstrating a 60% response rate to methotrexate. 3 However, methotrexate also carries the risk of myelosuppression and may not be the optimal therapy in immunocompromised at-risk patients. Recently, targeted immunomodulators such as apremilast 4 and janus kinase inhibitors (eg tofacitinib) 5 have been reported to lead to remission of GA and may also be considered as systemic agents for AOPAGA.…”